Literature DB >> 18041060

Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy.

Giuseppe Aprile1, Marco Ramoni, Dorothy Keefe, Stephen Sonis.   

Abstract

BACKGROUND: Colorectal cancer patients undergoing chemotherapy (CT) are likely to experience multiple concurrent toxicities that, rather than appearing singularly, may be associated with one another. Graphic and tabular representations of distance matrices were used to identify associations between toxicities and to define the strengths of these relations.
METHODS: Using a standardized data collection tool, electronic medical charts of 300 consecutive patients receiving either the combination of leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX); the combination of leucovorin, 5-FU, and irinotecan (FOLFIRI); or 5-FU) were retrospectively reviewed to record baseline demographic and clinical information. Treatment-related toxicities were recorded using National Cancer Institute Common Toxicity Criteria during the first cycle of CT. Using a distance matrix approach, an analysis of CT-induced toxicity associations was elaborated.
RESULTS: The graphic analysis, in which associations between toxicities were represented as links, identified 6 major hubs (fever, dehydration, fatigue, anorexia, pain, and weight loss), defined as central nodes with more connections than expected by chance. These were highly linked with minor nodes and provided evidence suggesting the existence of symptom clusters associated with CT-induced toxicities.
CONCLUSIONS: The application of distance matrix analyses to define CT-induced toxicity associations is new. The technique was effective in defining the global landscape of the binary relations among toxicities associated with Cycle 1 therapy. The coherent clinical picture emerging from the network provides a strong suggestion that the toxicities in each cluster share a common pathobiologic basis, which may provide an opportunity for intervention. These findings could become useful for the early prediction of co-occurring toxicities and, in the future, as a phenotyping framework for the pharmacogenomic analysis of individual responses to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18041060     DOI: 10.1002/cncr.23182

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.

Authors:  J M Bowen; I White; L Smith; A Tsykin; K Kristaly; S K Thompson; C S Karapetis; H Tan; P A Game; T Irvine; D J Hussey; D I Watson; D M K Keefe
Journal:  Support Care Cancer       Date:  2015-03-27       Impact factor: 3.603

Review 2.  Oral mucositis: the new paradigms.

Authors:  Douglas E Peterson; Rajesh V Lalla
Journal:  Curr Opin Oncol       Date:  2010-07       Impact factor: 3.645

3.  The role of IL-1β and TNF-α signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice.

Authors:  Logan B Smith; Michael C Leo; Caroline Anderson; Teresa J Wright; Kristianna B Weymann; Lisa J Wood
Journal:  Brain Behav Immun       Date:  2014-01-08       Impact factor: 7.217

4.  Intervention Protocol for Investigating Yoga Implemented During Chemotherapy.

Authors:  Stephanie J Sohl; Gurjeet S Birdee; Sheila H Ridner; Amy Wheeler; Sandra Gilbert; Danielle Tarantola; Jordan Berlin; Russell L Rothman
Journal:  Int J Yoga Therap       Date:  2016-01

5.  Symptom cluster analyses based on symptom occurrence and severity ratings among pediatric oncology patients during myelosuppressive chemotherapy.

Authors:  Christina Baggott; Bruce A Cooper; Neyssa Marina; Katherine K Matthay; Christine Miaskowski
Journal:  Cancer Nurs       Date:  2012 Jan-Feb       Impact factor: 2.592

6.  A brief yoga intervention implemented during chemotherapy: A randomized controlled pilot study.

Authors:  Stephanie J Sohl; Suzanne C Danhauer; Gurjeet S Birdee; Barbara J Nicklas; George Yacoub; Mebea Aklilu; Nancy E Avis
Journal:  Complement Ther Med       Date:  2016-04       Impact factor: 2.446

Review 7.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-04-21       Impact factor: 3.603

8.  Risk of unplanned visits for colorectal cancer outpatients receiving chemotherapy: a case-crossover study.

Authors:  Luisa Foltran; Giuseppe Aprile; Federica Edith Pisa; Paola Ermacora; Nicoletta Pella; Emiliana Iaiza; Elena Poletto; Stefania Eufemia Lutrino; Micol Mazzer; Mariella Giovannoni; Giovanni Gerardo Cardellino; Fabio Puglisi; Gianpiero Fasola
Journal:  Support Care Cancer       Date:  2014-04-13       Impact factor: 3.603

Review 9.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-07-11       Impact factor: 3.603

10.  New pathways for alimentary mucositis.

Authors:  Joanne M Bowen; Dorothy M K Keefe
Journal:  J Oncol       Date:  2008-09-23       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.